SpeB產(chǎn)品信息
別稱：SpeB,Streptopain,Exotoxin type B,Streptococcal cysteine proteinase
物種：Streptococcus pyogenes
屬性：Protein
標(biāo)記：Unconjugated
產(chǎn)品描述（Product Details）
SpeB is a unique recombinantly produced cysteine protease that digests antibodies from many species and subclasses in the hinge region, producing a homogenous pool of Fab fragments. The enzyme requires reducing conditions for activity on IgG.Human, mouse, rat, goat and sheep IgG are digested by SpeB, yielding Fab and Fc fragments. The primary digestion site on human IgG1 is KTHT / CPPCPAPE.
應(yīng)用說明（Application）
Purified and homogenous Fab fragments can be used in many applications, including:
1. Study monovalent binding of Fab fragments to the antigen.
2. Elimination of Fc-mediated effector functions.
3. Reduced unspecific binding from Fc interactions.
單位定義（Unit Definition）
One unit digests ≥ 95% of 1 μg human IgG1 when incubated in PBS with 5 mM DTT or TCEP, pH 7.4 at 37°C for 1 hour.
質(zhì)量控制（Quility Control）
Less than 1.0 EU per μg by the LAL method.
制劑（Formulation）
Supplied as 0.2 μm filtered solution in 20 mM Tris, 500 mM NaCl, 1 mM TCEP, pH7.0 with glycerol as protectant.
Contact us for customized product form or formulation.
運(yùn)輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲（Storage）
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt.
-70°C for 12 months under sterile conditions.
SpeB分子背景
SpeB is derived from Streptococcus pyogenes. It is an important streptococcal virulence factor which cleaves human fibronectin and degrades vitronectin. It also cleaves human IL1B precursor to form biologically active IL1B and can induce apoptosis in human monocytes and epithelial cells in vitro, reduces phagocytic activity in monocytic cells. Thus, it may play a role in bacterial colonization, invasion, and inhibition of wound healing.
關(guān)鍵字： SpeB;SpeB蛋白;SpeB重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。